BRAF/MEK inhibitors have limited intracranial efficacy and are theoretically considered unable to effectively cross the blood–brain barrier [129], yet clinical data have demonstrated efficacy in melanoma brain metastases [91]. The gene discussed is MAP2K7; the disease is melanoma.